AU4692399A – Cyclic hydroxamic acids as metalloproteinase inhibitors
– Google Patents
AU4692399A – Cyclic hydroxamic acids as metalloproteinase inhibitors
– Google Patents
Cyclic hydroxamic acids as metalloproteinase inhibitors
Info
Publication number
AU4692399A
AU4692399A
AU46923/99A
AU4692399A
AU4692399A
AU 4692399 A
AU4692399 A
AU 4692399A
AU 46923/99 A
AU46923/99 A
AU 46923/99A
AU 4692399 A
AU4692399 A
AU 4692399A
AU 4692399 A
AU4692399 A
AU 4692399A
Authority
AU
Australia
Prior art keywords
metalloproteinase inhibitors
hydroxamic acids
cyclic hydroxamic
cyclic
acids
Prior art date
1998-06-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU46923/99A
Inventor
Carl P. Decicco
Xiaohua He
Chu-Baio Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1998-06-17
Filing date
1999-06-17
Publication date
2000-01-05
1999-06-17
Application filed by DuPont Merck Pharmaceutical Co
filed
Critical
DuPont Merck Pharmaceutical Co
2000-01-05
Publication of AU4692399A
publication
Critical
patent/AU4692399A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
C07D213/30—Oxygen atoms
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders
A61P17/04—Antipruritics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P17/00—Drugs for dermatological disorders
A61P17/06—Antipsoriatics
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P19/00—Drugs for skeletal disorders
A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P21/00—Drugs for disorders of the muscular or neuromuscular system
A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P25/00—Drugs for disorders of the nervous system
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P27/00—Drugs for disorders of the senses
A61P27/02—Ophthalmic agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P31/04—Antibacterial agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P33/00—Antiparasitic agents
A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
A61P33/06—Antimalarials
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P35/00—Antineoplastic agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P35/00—Antineoplastic agents
A61P35/02—Antineoplastic agents specific for leukemia
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P37/00—Drugs for immunological or allergic disorders
A61P37/02—Immunomodulators
A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P7/00—Drugs for disorders of the blood or the extracellular fluid
A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P7/00—Drugs for disorders of the blood or the extracellular fluid
A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P9/00—Drugs for disorders of the cardiovascular system
A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P9/00—Drugs for disorders of the cardiovascular system
A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
C07D213/36—Radicals substituted by singly-bound nitrogen atoms
C07D213/40—Acylated substituent nitrogen atom
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D215/20—Oxygen atoms
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
C07D215/20—Oxygen atoms
C07D215/22—Oxygen atoms attached in position 2 or 4
C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07D—HETEROCYCLIC COMPOUNDS
C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C2601/00—Systems containing only non-condensed rings
C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
C07C2601/00—Systems containing only non-condensed rings
C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
C07C2601/14—The ring being saturated
AU46923/99A
1998-06-17
1999-06-17
Cyclic hydroxamic acids as metalloproteinase inhibitors
Abandoned
AU4692399A
(en)
Applications Claiming Priority (5)
Application Number
Priority Date
Filing Date
Title
US8955798P
1998-06-17
1998-06-17
US60089557
1998-06-17
US12759999P
1999-04-02
1999-04-02
US60127599
1999-04-02
PCT/US1999/013723
WO1999065867A1
(en)
1998-06-17
1999-06-17
Cyclic hydroxamic acids as metalloproteinase inhibitors
Publications (1)
Publication Number
Publication Date
AU4692399A
true
AU4692399A
(en)
2000-01-05
Family
ID=26780698
Family Applications (1)
Application Number
Title
Priority Date
Filing Date
AU46923/99A
Abandoned
AU4692399A
(en)
1998-06-17
1999-06-17
Cyclic hydroxamic acids as metalloproteinase inhibitors
Country Status (6)
Country
Link
US
(2)
US6429213B1
(en)
EP
(1)
EP1087937A1
(en)
JP
(1)
JP2002518368A
(en)
AU
(1)
AU4692399A
(en)
CA
(1)
CA2333554A1
(en)
WO
(1)
WO1999065867A1
(en)
Families Citing this family (83)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
EP1087937A1
(en)
*
1998-06-17
2001-04-04
Du Pont Pharmaceuticals Company
Cyclic hydroxamic acids as metalloproteinase inhibitors
GB9919776D0
(en)
*
1998-08-31
1999-10-27
Zeneca Ltd
Compoujnds
US6656448B1
(en)
*
2000-02-15
2003-12-02
Bristol-Myers Squibb Pharma Company
Matrix metalloproteinase inhibitors
US6989139B2
(en)
*
2000-02-15
2006-01-24
Bristol-Myers Squibb Pharma Company
Matrix metalloproteinase inhibitors
US6458822B2
(en)
*
2000-03-13
2002-10-01
Pfizer Inc.
2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
US6620823B2
(en)
*
2000-07-11
2003-09-16
Bristol-Myers Squibb Pharme Company
Lactam metalloprotease inhibitors
US6927216B2
(en)
2000-10-03
2005-08-09
Bristol-Myers Squibb Pharma Company
Cyclic sulfonyl compounds as inhibitors of metalloproteases
US6809093B2
(en)
*
2000-10-17
2004-10-26
H. Lee Moffitt Cancer & Research Institute, Inc.
2-substituted heterocyclic compounds
SE0100902D0
(en)
*
2001-03-15
2001-03-15
Astrazeneca Ab
Compounds
SE0100903D0
(en)
*
2001-03-15
2001-03-15
Astrazeneca Ab
Compounds
SE0103710D0
(en)
*
2001-11-07
2001-11-07
Astrazeneca Ab
Compounds
DE60231425D1
(en)
*
2001-11-13
2009-04-16
Shiseido Co Ltd
AZABICYCLOVER BINDING, MATRIX METAL PROTEASE INHIBITOR AND PREPARATION FOR SKIN
GB0216379D0
(en)
*
2002-07-13
2002-08-21
Astrazeneca Ab
Compounds
AU2002368151A1
(en)
*
2002-08-13
2004-02-25
Warner-Lambert Company Llc
Matrix metalloproteinase inhibitors and methods for identification of lead compounds
SE0202539D0
(en)
2002-08-27
2002-08-27
Astrazeneca Ab
Compounds
GB0221246D0
(en)
*
2002-09-13
2002-10-23
Astrazeneca Ab
Compounds
EP1541198A1
(en)
*
2003-12-05
2005-06-15
4Sc Ag
Cycloalkyl compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
WO2004056747A1
(en)
*
2002-12-23
2004-07-08
4Sc Ag
Dhodh-inhibitors and method for their identification
US7247736B2
(en)
2002-12-23
2007-07-24
4Sc Ag
Method of identifying inhibitors of DHODH
WO2004056746A1
(en)
*
2002-12-23
2004-07-08
4Sc Ag
Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
US7365094B2
(en)
2002-12-23
2008-04-29
4Sc Ag
Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents
CA2516328A1
(en)
*
2003-02-18
2004-09-02
Pfizer Inc.
Inhibitors of hepatitis c virus, compositions and treatments using the same
PL1622569T3
(en)
*
2003-04-24
2016-06-30
Incyte Holdings Corp
Aza spiro alkane derivatives as inhibitors of metallproteases
CN101407471A
(en)
2003-08-29
2009-04-15
小野药品工业株式会社
Compound capable of binding S1P receptor and pharmaceutical use thereof
JP4947406B2
(en)
2003-08-29
2012-06-06
小野薬品工業株式会社
Compound having S1P receptor binding ability and pharmaceutical use thereof
MXPA06004191A
(en)
2003-10-17
2007-01-19
Incyte Corp
Substituted cyclic hydroxamates as inhibitors of matrix metalloproteinases.
HUE028490T2
(en)
*
2003-12-02
2016-12-28
Univ Ohio State Res Found
Zn 2+ -chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
US7550487B2
(en)
*
2004-03-26
2009-06-23
Hoffmann-La Roche Inc.
Pyrrolidine-3,4-dicarboxamide derivatives
US7459562B2
(en)
*
2004-04-23
2008-12-02
Bristol-Myers Squibb Company
Monocyclic heterocycles as kinase inhibitors
TW200538453A
(en)
*
2004-04-26
2005-12-01
Bristol Myers Squibb Co
Bicyclic heterocycles as kinase inhibitors
US7439246B2
(en)
*
2004-06-28
2008-10-21
Bristol-Myers Squibb Company
Fused heterocyclic kinase inhibitors
SE0401763D0
(en)
*
2004-07-05
2004-07-05
Astrazeneca Ab
Compounds
US7648992B2
(en)
2004-07-05
2010-01-19
Astrazeneca Ab
Hydantoin derivatives for the treatment of obstructive airway diseases
SE0401762D0
(en)
*
2004-07-05
2004-07-05
Astrazeneca Ab
Novel compounds
ATE541830T1
(en)
*
2004-12-13
2012-02-15
Ono Pharmaceutical Co
AMINOCARBOXYLIC ACID DERIVATIVE AND MEDICAL USE THEREOF
SE0403085D0
(en)
*
2004-12-17
2004-12-17
Astrazeneca Ab
Novel componds
SE0403086D0
(en)
*
2004-12-17
2004-12-17
Astrazeneca Ab
Compounds
GB0505969D0
(en)
2005-03-23
2005-04-27
Novartis Ag
Organic compounds
US7470693B2
(en)
*
2005-04-21
2008-12-30
Bristol-Myers Squibb Company
Oxalamide derivatives as kinase inhibitors
TW200738676A
(en)
*
2005-06-20
2007-10-16
Schering Corp
Heteroatom-linked substituted piperidines and derivatives thereof useful as histamine H3 antagonists
WO2007033196A1
(en)
*
2005-09-14
2007-03-22
Bristol-Myers Squibb Company
Met kinase inhibitors
WO2007035428A1
(en)
*
2005-09-15
2007-03-29
Bristol-Myers Squibb Company
Met kinase inhibitors
NZ569135A
(en)
2005-12-30
2011-08-26
Novartis Ag
3,5-Substituted piperidine compounds as renin inhibitors
US7709496B2
(en)
2006-04-06
2010-05-04
Glaxo Group Limited
Antibacterial agents
US7910108B2
(en)
*
2006-06-05
2011-03-22
Incyte Corporation
Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases
AR063628A1
(en)
*
2006-11-08
2009-02-04
Bristol Myers Squibb Co
USEFUL PIRIDINONE COMPOUNDS FOR CANCER TREATMENT
TW200831488A
(en)
*
2006-11-29
2008-08-01
Astrazeneca Ab
Novel compounds
EP2142498A2
(en)
2007-04-02
2010-01-13
Institute for Oneworld Health
Cftr inhibitor compounds and uses thereof
EP2181105B1
(en)
2007-06-25
2015-04-29
Novartis AG
N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
WO2009015166A1
(en)
2007-07-24
2009-01-29
Bristol-Myers Squibb Company
Piperidine derivatives as modulators of chemokine receptor activity
SI2235002T1
(en)
2008-01-23
2013-06-28
Bristol-Myers Squibb Company
4-pyridinone compounds and their use for cancer
CN101977905B
(en)
2008-01-23
2014-07-02
百时美施贵宝公司
4-pyridinone compounds and their use for cancer
WO2009102893A2
(en)
2008-02-14
2009-08-20
Amira Pharmaceuticals, Inc.
CYCLIC DIARYL ETHER COMPOUNDS AS ANTAGONISTS OF PROSTAGLANDIN D2 receptors
NZ587799A
(en)
2008-03-25
2012-06-29
Affectis Pharmaceuticals Ag
Novel p2x7r antagonists and their use
US8426449B2
(en)
*
2008-04-02
2013-04-23
Panmira Pharmaceuticals, Llc
Aminoalkylphenyl antagonists of prostaglandin D2 receptors
WO2009131957A2
(en)
2008-04-21
2009-10-29
Institute For Oneworld Health
Compounds, compositions and methods comprising oxadiazole derivatives
KR101325367B1
(en)
2008-07-03
2013-11-11
판미라 파마슈티칼스, 엘엘씨
Antagonists of prostaglandin d2 receptors
WO2010057118A2
(en)
2008-11-17
2010-05-20
Amira Pharmaceuticals, Inc.
Heterocyclic antagonists of prostaglandin d2 receptors
EA020874B1
(en)
*
2008-12-22
2015-02-27
Кемосентрикс, Инк.
C5aR ANTAGONISTS
US8410144B2
(en)
2009-03-31
2013-04-02
Arqule, Inc.
Substituted indolo-pyridinone compounds
EA201101479A1
(en)
2009-04-14
2012-05-30
Эффектис Фармасьютиклз Аг
NEW P2X7R ANTAGONISTS AND THEIR APPLICATION
US8343976B2
(en)
2009-04-20
2013-01-01
Institute For Oneworld Health
Compounds, compositions and methods comprising pyrazole derivatives
BRPI1011247A2
(en)
2009-06-09
2016-06-21
California Capital Equity Llc
isoquinoline, quinoline and quinazoline derivatives as hedgehog signaling inhibitors
US9078902B2
(en)
2009-06-09
2015-07-14
Nantbioscience, Inc.
Triazine derivatives and their therapeutical applications
KR20120026612A
(en)
2009-06-09
2012-03-19
아브락시스 바이오사이언스, 엘엘씨
Benzyl substituted triazine derivatives and their therapeutical applications
US8258158B2
(en)
*
2009-09-11
2012-09-04
Hoffmann-La Roche Inc.
HSL inhibitors useful in the treatment of diabetes
US8293925B2
(en)
*
2009-09-21
2012-10-23
Chemocentryx, Inc.
Pyrrolidinone carboxamide derivatives
CN102812000A
(en)
2010-01-06
2012-12-05
潘米拉制药公司
Dp2 Antagonist And Uses Thereof
BR112012033075B1
(en)
*
2010-06-24
2021-06-01
Chemocentryx, Inc
C5A RECEPTOR ANTAGONIST REPLACED PIPERIDINE COMPOUND, PHARMACEUTICAL COMPOSITION, AND, USE OF COMPOUND
WO2012071369A2
(en)
2010-11-24
2012-05-31
The Trustees Of Columbia University In The City Of New York
A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease
WO2012110190A1
(en)
2011-02-17
2012-08-23
Affectis Pharmaceuticals Ag
Novel p2x7r antagonists and their use
WO2012163792A1
(en)
2011-05-27
2012-12-06
Affectis Pharmaceuticals Ag
Novel p2x7r antagonists and their use
WO2012163456A1
(en)
2011-05-27
2012-12-06
Affectis Pharmaceuticals Ag
Novel p2x7r antagonists and their use
EP2775906B1
(en)
2011-11-11
2019-07-03
Yale University
Evaluation of presence of and vulnerability to atrial fibrillation and other indications using matrix metalloproteinase-based imaging
WO2013166037A1
(en)
2012-05-01
2013-11-07
The Trustees Of Columbia University In The City Of New York
Non-retinoid antagonists for treatment of eye disorders
CA2881566A1
(en)
2012-07-19
2014-01-23
Yohei Ikuma
1-(cycloalkyl-carbonyl)proline derivative
US9944644B2
(en)
2013-03-14
2018-04-17
The Trustees Of Columbia University In The City Of New York
Octahydropyrrolopyrroles their preparation and use
US10273243B2
(en)
2013-03-14
2019-04-30
The Trustees Of Columbia University In The City Of New York
4-phenylpiperidines, their preparation and use
US9938291B2
(en)
2013-03-14
2018-04-10
The Trustess Of Columbia University In The City Of New York
N-alkyl-2-phenoxyethanamines, their preparation and use
US9637450B2
(en)
2013-03-14
2017-05-02
The Trustees Of Columbia University In The City Of New York
Octahydrocyclopentapyrroles, their preparation and use
CA2947174C
(en)
2014-04-30
2023-02-28
The Trustees Of Columbia University In The City Of New York
Substituted 4-phenylpiperidines, their preparaiton and use
BR112017028448A2
(en)
2015-07-02
2018-08-28
Horizon Orphan Llc
ado-resistant cysteamine analogs and uses thereof
WO2019170543A1
(en)
2018-03-07
2019-09-12
Bayer Aktiengesellschaft
Identification and use of erk5 inhibitors
Family Cites Families (12)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US4207091A
(en)
*
1976-02-09
1980-06-10
Ciba-Geigy Corporation
Method of preventing plants from damage by frost
CH621043A5
(en)
*
1976-02-09
1981-01-15
Ciba Geigy Ag
Process for protecting plants against frost damage, and composition for carrying out this process.
US5114953A
(en)
*
1990-11-21
1992-05-19
University Of Florida
Treatment for tissue ulceration
ATE198326T1
(en)
1995-04-20
2001-01-15
Pfizer
ARYLSULFONAMIDO-SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF MMP AND TNF
US6211154B1
(en)
*
1995-06-07
2001-04-03
Cor Therapeutics, Inc.
Ketoheterocyclic inhibitors of factor Xa
US6153757A
(en)
1995-12-08
2000-11-28
Agouron Pharmaceuticals, Inc.
Metalloproteinase inhibitors and intermediates useful for their preparation
DE69624081T2
(en)
1995-12-20
2003-06-12
Hoffmann La Roche
Matrix metalloprotease inhibitors
US5787969A
(en)
*
1995-12-22
1998-08-04
Hughes Electronics Corporation
Flexible heat transport design for development applications
EP0818442A3
(en)
1996-07-12
1998-12-30
Pfizer Inc.
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
EP0934259B1
(en)
1996-10-16
2002-09-18
American Cyanamid Company
Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors
US6107291A
(en)
*
1997-12-19
2000-08-22
Amgen Inc.
Azepine or larger medium ring derivatives and methods of use
EP1087937A1
(en)
*
1998-06-17
2001-04-04
Du Pont Pharmaceuticals Company
Cyclic hydroxamic acids as metalloproteinase inhibitors
1999
1999-06-17
EP
EP99930371A
patent/EP1087937A1/en
not_active
Withdrawn
1999-06-17
CA
CA002333554A
patent/CA2333554A1/en
not_active
Abandoned
1999-06-17
WO
PCT/US1999/013723
patent/WO1999065867A1/en
not_active
Application Discontinuation
1999-06-17
JP
JP2000554694A
patent/JP2002518368A/en
active
Pending
1999-06-17
US
US09/335,086
patent/US6429213B1/en
not_active
Expired – Lifetime
1999-06-17
AU
AU46923/99A
patent/AU4692399A/en
not_active
Abandoned
2002
2002-06-20
US
US10/177,235
patent/US6858626B2/en
not_active
Expired – Lifetime
Also Published As
Publication number
Publication date
CA2333554A1
(en)
1999-12-23
EP1087937A1
(en)
2001-04-04
JP2002518368A
(en)
2002-06-25
WO1999065867A1
(en)
1999-12-23
US6429213B1
(en)
2002-08-06
US20030139597A1
(en)
2003-07-24
US6858626B2
(en)
2005-02-22
Similar Documents
Publication
Publication Date
Title
AU4692399A
(en)
2000-01-05
Cyclic hydroxamic acids as metalloproteinase inhibitors
AU4074799A
(en)
1999-11-29
Substituted aryl hydroxamic acids as metalloproteinase inhibitors
IL144783A0
(en)
2002-06-30
Sulfamato hydroxamic acid metalloprotease inhibitor
GB9912961D0
(en)
1999-08-04
Metalloprotease inhibitors
AU3102397A
(en)
1998-01-07
Metalloprotease inhibitors
GB9401129D0
(en)
1994-03-16
Hydroxamic acid derivatives as metalloproteinase inhibitors
AU2594799A
(en)
1999-08-30
Novel cyclic sulfonamide derivatives as metalloproteinase inhibitors
AU4723799A
(en)
2000-01-10
Protease inhibitors
AU5634999A
(en)
2000-03-21
Hydroxamic acid derivatives as proteinase inhibitors
PL350452A1
(en)
2002-12-16
Dihetero-substituted metalloprotease inhibitors
AU6764400A
(en)
2001-03-13
Hydroxamic acid compounds useful as matrix metalloproteinase inhibitors
IL139248A0
(en)
2001-11-25
Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
AU4092799A
(en)
1999-12-06
Protease inhibitors
AU9110298A
(en)
1999-12-06
Protease inhibitors
AU1393900A
(en)
2000-06-05
Morpholino-ethoxybenzofuran protease inhibitors
AU1588901A
(en)
2001-06-06
Protease inhibitors
AU4564499A
(en)
1999-12-30
Protease inhibitors
AU2713100A
(en)
2000-07-31
Protease inhibitors
AU1474801A
(en)
2001-06-06
Protease inhibitors
AU3888200A
(en)
2000-10-04
Protease inhibitors
AU1474701A
(en)
2001-06-06
Protease inhibitors
AU4066900A
(en)
2000-10-16
Protease inhibitors
AU1474601A
(en)
2001-06-06
Protease inhibitors
AU5128298A
(en)
1998-06-22
Metalloproteinase inhibitors
AU7990000A
(en)
2001-04-30
Neuraminidase inhibitors
Legal Events
Date
Code
Title
Description
2001-03-08
MK6
Application lapsed section 142(2)(f)/reg. 8.3(3) – pct applic. not entering national phase
